BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

Altre lingue Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Azioni

2315

CNE100005D27

Prezzo di chiusura Hong Kong S.E. Altri mercati azionari 00:00:00 11/07/2024			Variaz. 5gg	Var. 1 gen.
7,59 ^CNY	+1,88%		+1,61%	-36,64%

06/05	Biocytogen stipula un accordo di valutazione e potenziale licenza con Biocopy per gli anticorpi TCR-mimici	CI
26/04	Le perdite di Biocytogen Pharmaceuticals si riducono nel 2023	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Biocytogen Awarded U.S. Patent for RenLite Common Light Chain Mouse Platform	24/06
XtalPi Inc. announced that it has received CNY 337 million in funding from Shanghai Guosheng Investment Group, Biocytogen Pharmaceuticals Co., Ltd., FaaS Capital Longevity Limited and other investors	04/06
Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	06/05
Biocytogen Pharmaceuticals' Loss Narrows in 2023	26/04
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates	26/03
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	25/03
Biocytogen Pharmaceuticals Co., Ltd Announces Antibody Evaluation and Option Agreement with Gilead Sciences, Inc	19/02
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	24/01
Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics	23/01
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	09/01
Biocytogen Pharmaceuticals Gets License for Radiance Biopharma's Tumor Drug	08/01
Biocytogen Pharmaceuticals Co., Ltd. Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	08/01
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	28/12
Biocytogen Pharmaceuticals Co., Ltd. and CtM Biotech Co., Ltd Achieve Milestone Progress in Co-Developing A TCR-Mimic Antibody-Based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	27/12
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	20/12
Biocytogen Strikes Multi-Target Antibody Deal With Neurocrine Biosciences	20/12
Biocytogen Pharmaceuticals Co., Ltd. Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	20/12
Biocytogen Pharmaceuticals (Beijing) signs antibody evaluation, option and license agreement with Ona Therapeutics	19/12
Biocytogen, Ona Therapeutics Sign Agreement for Development of Antibody-Drug Conjugates	18/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Azioni

2315

CNE100005D27

Altre lingue

Filtri